Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07483294 · ClinicalTrials.gov registry record
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
A clinical trial of Psychosis; Acute, sponsored by Northwell Health.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07483294 is a study of Psychosis; Acute that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07483294, a study of Psychosis; Acute, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with either risperidone or aripiprazole for 12 weeks, with dosage and titration followed by standard clinical care. A comprehensive clinical and neuroimaging assessments will be performed before and after treatment.
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (1)
New York
- Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2030-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07483294
The ClinicalTrials.gov registry entry for NCT07483294 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychosis; Acute appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT07483294 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07483294 about?
NCT07483294 is a clinical study titled "Cerebellum-based Imaging Neural Markers for Antipsychotic Response". This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with ...
What is the current status of trial NCT07483294?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-11-01. Estimated completion is 2030-06-01.
What conditions does trial NCT07483294 study?
This clinical trial studies the following conditions: Psychosis; Acute.
What interventions are being tested in trial NCT07483294?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT07483294?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07483294 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.